NHPD Site Licensing for Manufacturers and Importers — What It Requires

A nutraceutical company based in Ontario has been selling products under the Natural Health Products Regulations for several years. A new product line requires a manufacturing partner in British Columbia. Before the partnership can proceed, a question arises that neither party has fully addressed: does the BC manufacturer hold a valid NHP site licence for the relevant activities, and does the Ontario company’s own site licence cover importation if any ingredients are sourced internationally?

Site licensing under the Natural Health Products Regulations (SOR/2003-196) is a prerequisite for selling natural health products in Canada, yet it is frequently misunderstood — particularly regarding which activities require a licence, what GMP standards apply, and what ongoing obligations a licence holder must meet. This article addresses those questions for manufacturers and importers operating in the Canadian NHP market.

What Is an NHP Site Licence?

An NHP site licence is an authorization issued by Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) that permits a specific facility to perform specific NHP-related activities. Under Section 8 of the NHP Regulations, no person may manufacture, package, label, or import a natural health product for sale unless the person holds a site licence that authorizes those activities.

The site licence is issued to a specific legal entity for a specific physical location. A company with multiple facilities must hold a separate site licence for each facility. A company that both manufactures and imports must hold a site licence that covers both activities — or must ensure that its manufacturing and importing activities are performed at licensed facilities.

Which Activities Require a Site Licence?

The NHP Regulations require a site licence for the following activities when performed in relation to NHPs for sale:

• Manufacturing: The production of a natural health product, including compounding, mixing, granulating, coating, tableting, encapsulating, and filling
• Packaging: Placing an NHP into its immediate container
• Labelling: Applying a label to an NHP or its container
• Importing: Bringing an NHP into Canada for sale

Testing is not explicitly listed as a licensed activity under the NHP Regulations, but testing performed as part of the quality control function of a licensed manufacturer is covered by the manufacturer’s site licence. Contract testing laboratories that perform testing on NHPs on behalf of licensed manufacturers may operate under the manufacturer’s quality system without a separate NHP site licence, though this should be confirmed with Health Canada for specific situations.

Wholesale distribution — the sale of NHPs between licensed parties without performing manufacturing, packaging, labelling, or importing — does not require a site licence under the NHP Regulations, though it may be subject to other regulatory requirements.

GMP Requirements for NHP Site Licence Holders

The GMP requirements for NHP site licence holders are set out in Schedule 2 of the NHP Regulations, which incorporates by reference the Good Manufacturing Practices guidance document published by Health Canada. The NHP GMP requirements are less prescriptive than the pharmaceutical GMP requirements in Division 2 of the Food and Drug Regulations, but they cover the same fundamental areas:

• Personnel: Qualifications, training, and hygiene requirements
• Premises: Design, construction, and maintenance to prevent contamination
• Equipment: Qualification, calibration, and maintenance
• Sanitation: Written cleaning and sanitation programs
• Raw materials: Supplier qualification, receipt, testing, and release
• Manufacturing operations: Documented procedures, in-process controls, and batch records
• Quality assurance: Independent QA function with authority to approve or reject
• Finished product testing: Specifications, testing, and release criteria
• Records: Retention and accessibility requirements
• Recalls: Written recall procedure

For manufacturers of NHPs that are also subject to pharmaceutical GMP requirements (e.g., products that straddle the NHP/drug boundary), the more stringent pharmaceutical GMP requirements will generally apply. Requirements may vary depending on the product classification and the regulatory pathway.

The Site Licence Application Process

Step 1: Determine the Required Activities

Before applying, identify all activities that will be performed at the facility and confirm that a site licence is required for each. If the facility will perform manufacturing, packaging, labelling, and importing, all four activities should be included in the application.

Step 2: Prepare the GMP Evidence Package

The site licence application must include evidence that the facility meets the GMP requirements in Schedule 2. The evidence package typically includes:

• A description of the facility (floor plan, equipment list, personnel structure)
• A summary of the quality management system (QMS)
• Key SOPs (manufacturing, quality control, sanitation, recall)
• Evidence of personnel qualifications and training
• Equipment qualification and calibration records (for critical equipment)

Health Canada may conduct a site inspection before issuing a new site licence, particularly for new applicants or for facilities seeking to add high-risk activities. The inspection will assess whether the facility’s GMP practices match the documentation submitted.

Step 3: Submit the Application

Site licence applications are submitted through Health Canada’s NNHPD online portal. The application must include:

• Applicant information (legal name, address, contact)
• Facility information (physical address, activities requested)
• Product classes covered (vitamins, minerals, herbal remedies, etc.)
• GMP evidence package
• Declaration of GMP compliance

Health Canada will review the application and may issue a deficiency notice requesting additional information. Response timelines are specified in the notice.

Step 4: Maintain the Site Licence

Once issued, the site licence must be maintained through ongoing GMP compliance and timely notification of changes. Key ongoing obligations include:

• Annual renewal: NHP site licences must be renewed annually. The renewal application must confirm that GMP compliance is maintained and that no significant changes have occurred that would affect the licence scope.
• Change notification: Significant changes to the facility, activities, or quality system must be notified to Health Canada. The definition of “significant change” is not exhaustively defined in the regulations, but changes that affect the scope of the licence or the GMP compliance status are clearly captured.
• Adverse reaction reporting: Site licence holders must report serious adverse reactions associated with their products to Health Canada within 15 days of becoming aware of the reaction.
• Record retention: Records must be retained for a period specified in the NHP Regulations — generally one year beyond the expiry date of the product batch.

Common Site Licensing Compliance Issues

Scope gaps: A facility performing activities not covered by its site licence is in violation of the NHP Regulations. This can occur when a facility expands its activities (e.g., adding importation to an existing manufacturing licence) without updating its site licence.

GMP documentation gaps: Site licence holders that have not maintained their GMP documentation — outdated SOPs, incomplete batch records, lapsed equipment calibrations — risk non-compliance findings during Health Canada inspections.

Change notification failures: Facilities that make significant changes to their operations without notifying Health Canada may find that their site licence no longer accurately reflects their activities, creating compliance risk.

Importer obligations: Importers often underestimate their GMP obligations. An importer is responsible for ensuring that the products they import meet the NHP Regulations’ quality requirements, which means they must have a quality system capable of receiving, testing, and releasing imported products.

Practical Checklist: NHP Site Licence Compliance

• Confirm site licence covers all activities performed at the facility (manufacturing, packaging, labelling, importing)
• Confirm site licence is current (not expired or suspended); check Health Canada’s public database
• GMP documentation current: SOPs, batch records, equipment records, training records
• Quality assurance function in place with authority to approve or reject
• Supplier qualification program in place for all raw material suppliers
• Finished product specifications and testing procedures documented
• Recall procedure in place and tested
• Annual renewal submitted on time
• Change notification procedure in place; significant changes notified to Health Canada
• Adverse reaction reporting procedure in place; staff trained on reporting obligations
• Records retained per NHP Regulations requirements

NHP site licensing is a foundational compliance requirement for the Canadian natural health products market. Requirements may vary depending on the activities performed, the product classes involved, and the facility’s compliance history. We recommend a periodic compliance review to confirm that the site licence remains accurate and that GMP practices are maintained.

At Androxa, we support NHP manufacturers and importers with site licence applications, GMP gap assessments, and quality system development. Contact our team at testing-lab.ca to discuss your site licensing needs.